Diffuse Large B Cell Lymphoma Prognosis
Revised IPI score calculator for DLBCL prognosis: evaluate 5 factors (age, stage, LDH, ECOG, extranodal) and get 4-year survival estimates with risk classification.
About This Calculator
The Diffuse Large B Cell Lymphoma (DLBCL) Prognosis Calculator uses the Revised International Prognostic Index (R-IPI) to estimate survival outcomes in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. DLBCL is the most common type of non-Hodgkin lymphoma, accounting for approximately 30-40% of all lymphoma cases worldwide.
The R-IPI evaluates five independent prognostic factors: age over 60 years, Ann Arbor stage III or IV disease, elevated serum lactate dehydrogenase (LDH), ECOG/Zubrod performance status of 2 or higher, and involvement of more than one extranodal site. Each factor contributes 1 point for a total score ranging from 0 to 5. Based on the total score, patients are classified into three risk groups: Very Good (0 points), Good (1-2 points), and Poor (3-5 points), with corresponding 4-year overall survival rates of 94%, 79%, and 55% respectively.
Regional Notes
United States: The NCCN-IPI (National Comprehensive Cancer Network International Prognostic Index) is also commonly used in US practice, which uses a weighted scoring system (0-8 points) with age categorized by decades (≤40, 41-60, 61-70, >70) and LDH expressed as a ratio to the upper limit of normal. However, the R-IPI remains widely cited in clinical trials and standard practice.
United Kingdom: NICE guidelines recommend the use of the IPI score for risk stratification in DLBCL. The R-IPI is adopted across NHS hematology centers for treatment planning and patient counseling. The UK has a slightly higher incidence rate of approximately 15-20 cases per 100,000 population annually.
India: DLBCL is the most common subtype of NHL in India, comprising up to 45% of cases. The R-IPI scoring system is used in major cancer centers. Special considerations include the higher prevalence of EBV-associated DLBCL and the younger median age at presentation (40-50 years) compared to Western populations. The IPI remains a practical tool given the cost-effectiveness and widespread availability of the required clinical and laboratory parameters.
Frequently Asked Questions
What is the Revised IPI score for DLBCL?
The Revised International Prognostic Index (R-IPI) is a clinical tool that uses five factors — age over 60, Ann Arbor stage III/IV, elevated serum LDH, ECOG performance status 2 or higher, and more than one extranodal site — to predict outcomes in diffuse large B-cell lymphoma patients treated with rituximab-containing chemotherapy. Each factor scores 1 point for a total of 0-5, stratifying patients into Very Good (0), Good (1-2), or Poor (3-5) risk groups.
What are the DLBCL risk groups in the R-IPI?
The R-IPI stratifies DLBCL patients into three risk groups: Very Good (score 0, 94% 4-year overall survival), Good (score 1-2, 79% 4-year OS), and Poor (score 3-5, 55% 4-year OS). The 4-year progression-free survival rates are 94%, 80%, and 53% respectively. This scoring system was validated in the rituximab era and is widely used by hematologists worldwide.
How is the ECOG performance status scored?
The ECOG/Zubrod performance status ranges from 0 to 5: 0 (fully active, able to carry on all pre-disease activities without restriction), 1 (restricted in physically strenuous activity but ambulatory and able to carry out light work), 2 (ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours), 3 (capable of only limited self-care, confined to bed or chair more than 50% of waking hours), 4 (completely disabled), and 5 (dead). For the R-IPI, a score of 2 or higher is considered a risk factor.
What is the difference between IPI and R-IPI?
The original IPI was developed before rituximab became standard therapy and categorized patients into four risk groups. The Revised IPI (R-IPI) was validated in patients treated with R-CHOP and uses the same five factors but reclassifies into three groups (Very Good, Good, Poor). The R-IPI provides more accurate prognosis prediction in the modern treatment era with improved survival outcomes across all groups.
What is considered elevated serum LDH in DLBCL?
Serum LDH is considered elevated when it exceeds the upper limit of normal for the testing laboratory (typically 140-280 U/L). Elevated LDH in DLBCL indicates high tumor burden and rapid cell turnover, making it one of the five independent prognostic factors in the IPI scoring system. It is the single most important laboratory marker for DLBCL prognosis.
What does more than one extranodal site mean?
An extranodal site is any location of lymphoma involvement outside of lymph nodes, such as the bone marrow, liver, lungs, GI tract, CNS, or skin. Having more than one extranodal site is considered a risk factor in the IPI scoring system. Common extranodal sites in DLBCL include the stomach, small intestine, bone, thyroid, and salivary glands.
How is DLBCL staged using the Ann Arbor system?
The Ann Arbor staging system has four stages: Stage I involves a single lymph node region; Stage II involves two or more regions on the same side of the diaphragm; Stage III involves regions on both sides of the diaphragm; and Stage IV involves disseminated involvement of extralymphatic organs. Stages III and IV are considered advanced disease and carry 1 point in the IPI score.
Is this calculator suitable for all DLBCL subtypes?
The R-IPI was validated primarily for de novo diffuse large B-cell lymphoma treated with R-CHOP. It may have limited applicability for primary CNS lymphoma, transformed indolent lymphoma, HIV-associated DLBCL, or post-transplant lymphoproliferative disorders. Always consult a hematologist for personalized prognostic assessment and treatment decisions.